---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-016660"
form_type: "8-K"
ticker: null
cik: "0001840904"
company_name: "ATAI Life Sciences N.V."
filed_at: "2025-04-30T23:59:59+00:00"
generated_at: "2026-05-23T02:40:06.159441+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ATAI Life Sciences CBO Sahil Kirpekar departs; separation and consulting agreements finalized

## Summary
- Sahil Kirpekar terminated as Chief Business Officer effective April 2, 2025; separation agreement signed April 24.
- Separation provides up to $5,000 legal fee reimbursement, extended option exercise to Aug 14, 2025, $3,400 learning costs, $12,000 relocation, company computer retention.
- Consulting agreement effective April 3 for transitional BD support through Dec 31, 2025; allows vesting of 50% of unvested options from Mar 2023 and Mar 2024 grants.
- No replacement named; Kirpekar continues as consultant for business development transition.

## SEC filing metadata
- accession: 0001140361-25-016660
- form_type: 8-K
- cik: 0001840904
- company_name: ATAI Life Sciences N.V.
- filed_at: 2025-04-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840904/000114036125016660/0001140361-25-016660-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840904/000114036125016660/ef20048125_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-016660
- JSON: https://secwatch.observer/filing/0001140361-25-016660.json
- Plain text: https://secwatch.observer/filing/0001140361-25-016660.txt

## Key facts
- Executive change
  Sahil Kirpekar was terminated as Chief Business Officer at ATAI Life Sciences N.V..
  - Action: terminated
  - Role: Chief Business Officer
  source text: Sahil Kirpekar’s employment as Chief Business Officer of atai Life Sciences US, Inc. (“atai US”) and its affiliates, including atai Life Sciences N.V. (the “Company”), terminated effective April 2, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840904/000114036125016660/0001140361-25-016660-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.